There is an apparent expansion of CD34 cells during the evolution from MDS to secondary AML [29], and CD34 is a prognostic biomarker for ALL [30], hence MDS-AML and B-ALL may both be valid targets for combination treatments with PTC596 and S63845 or trametinib. This evidence concerns the gene CD34 and acute myeloid leukemia.